On September 24, a wallet labeled as Bitget moved about $19.7 million in USDT0 on the Arbitrum network and converted it into roughly 7,111 Ether (ETH) within six minutes. The trades used decentralized services UniswapX and 1inch Fusion, which route swaps across multiple liquidity sources rather than a traditional exchange order book. Some trades executed at premiums up to 5% above the ETH spot price. It is unclear if these transfers were authorized or not. This activity highlights the use of decentralized trading on Ethereum layer-2 networks and cross-chain stablecoins like USDT0.
The Bitget-labeled wallet's recent $19.7 million USDT0 to Ether swap is notable context for readers. For those tracking cryptocurrency markets, here is Pluang's snapshot as of Sep 25, 2026 03:01 WIB: out of 50 major cryptocurrencies priced on Pluang, 44 rose and 5 fell. Notable movers include SXP down 46.27% at Rp37, LTC up 17.23% at Rp1.279.121 with 60% sell order activity, and ONE down 16.49% at Rp44 with 52% buy order activity.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
